Anti-Mouse Thy1.1 (CD90.1) [Clone 19E12] — Purified in vivo PLATINUM™ Functional Grade

Clone 19E12 is primarily used in in vivo mouse studies to deplete cells expressing Thy1.1 (CD90.1), a surface glycoprotein present on certain mouse T cells and used as a transgenic marker in cell transfer and immunology experiments. The antibody is administered to mice to specifically remove Thy1.1-positive cells by immune-mediated mechanisms, enabling studies on cell function, lineage, and immune responses.

Essential details:

• Thy1.1 (CD90.1) is a marker on distinct mouse strains (e.g., AKR/J, PL) and is often introduced by transgenesis to tag specific cell populations in genetically engineered models.

• Depletion mechanism: Injecting clone 19E12 into mice leads to the selective elimination of Thy1.1+ cells, which can include native T cells or genetically labeled populations in adoptive transfer studies.

• Experimental applications:

  • Functional studies: Researchers deplete Thy1.1+ cells to determine their roles in immunity, tolerance, cancer models, or other physiological/pathological processes.
  • Transgenic studies: Cells engineered to express Thy1.1 (for tracking or functional separation) can be selectively removed to assess their contribution in vivo.
  • Cytotoxicity and tumor models: 19E12 has been used to mediate specific T cell or antibody-driven lysis of Thy1.1+ tumor cells in vivo and in vitro, and to pretarget cytokines to tumors expressing this marker.

• Additional uses:

  • Flow cytometry/immunohistochemistry: 19E12 can also be used ex vivo for detecting and sorting Thy1.1+ populations, but its key in vivo utility is depletion.

• Technical note:

  • The effectiveness and specificity of depletion should be validated for each experimental design, depending on dosing, antibody lot, and mouse strain.
  • 19E12 is distinct from other anti-Thy1 clones, so staining and depletion are sometimes performed with different clones to avoid detection interference.

In summary, clone 19E12 is a tool for targeted in vivo depletion of mouse Thy1.1+ cells, crucial for functional studies of cell populations that naturally or transgenically express this marker.

The antibody clone 19E12 is most commonly used to target mouse Thy1.1 (CD90.1). In the literature, researchers often use 19E12 in combination with other antibodies and proteins, especially those relevant for immunology, stem cell biology, and cancer research, though precise combinations vary by application.

Commonly used antibodies and proteins with 19E12 include:

• Rat monoclonal antibody R17 208: This antibody has been specifically cited as being combined with 19E12 to enhance antitumor activity in mouse models.
• Other lineage or cell population markers in flow cytometry: These typically include antibodies against mouse CD3, CD4, CD8, CD45, or other immune markers to distinguish T cell subpopulations or monitor depletion/enrichment of Thy1.1-positive cells (e.g., in immune cell tracking, stem cell sorting, transplantation models).
• Bispecific or fusion proteins: 19E12 has been engineered into bispecific hybrid antibodies to recruit effector cells against Thy1.1+ tumor cells, and conjugated with biotin to increase localization of agents such as human tumor necrosis factor alpha (TNF?) at tumor sites.
• Antibodies for depletion studies: Researchers frequently use 19E12 alongside other depletion antibodies (e.g., anti-CD8, anti-CD4) to selectively remove defined T cell populations or to control for specificity when depleting Thy1.1-expressing transgenic or endogenous cells.

Typical experimental combinations:

• In flow cytometry and immunohistochemistry, 19E12 is co-used with antibodies for other mouse immune or stem cell surface markers.
• In functional studies (tumor or immune response), 19E12 may be paired with checkpoint blockade antibodies or cytokine fusion proteins (e.g., anti-PD-1/PD-L1, L19-TNF?)—though L19 and similar are more commonly used in human/rat studies, not directly mouse Thy1.1.
• When engineering bispecific or ADC-type constructs, 19E12 may be linked to proteins such as biotin, TNF?, or other cytokines for focused therapeutic or imaging applications.

Key insight: While rat R17 208 is specifically documented as combined with 19E12 for enhanced antitumor efficacy, most other combinations depend on experimental design, such as multi-color flow cytometry panels or depletion schemas involving core mouse lineage markers.

If a particular experimental technique or disease model is specified, it is possible to provide a more detailed list of commonly paired antibodies or detection proteins.

Clone 19E12 is a mouse monoclonal antibody specific for the murine Thy1.1 (CD90.1) alloantigen and is widely cited in scientific literature, particularly in immunology and cell biology. Key findings and uses from these citations are:

• Specificity and Function: 19E12 binds specifically to mouse Thy1.1 (CD90.1), a GPI-linked glycoprotein important for T cell activation, cell-cell interactions, and identification of T cell populations in transgenic and adoptive transfer models.

• Use in Cell Depletion and Tracking: 19E12 is commonly used for selective depletion of Thy1.1+ cells in mice, both in naturally occurring Thy1.1+ T cells and in cells engineered to express Thy1.1 for tracking or adoptive transfer studies.

• Antitumor Activity: Early studies showed that 19E12 exhibited antitumor effects in mouse models with AKR SL3/SL2 leukemia, especially when combined with other antibodies (e.g., R17 208). This supported its use as a tool for targeting or manipulating immune/tumor cell populations.

• Bispecific Antibody Engineering: The 19E12 antibody has been engineered into bispecific antibodies to focus T cell activity against Thy1.1-expressing tumor cells, showing efficient tumor cell lysis in vitro.

• Pretargeting Strategies: Biotinylated 19E12 has been used in pretargeting approaches to increase local delivery of therapeutic molecules like tumor necrosis factor alpha (TNF-?) to tumors in mouse models, enhancing therapeutic concentration and persistence at the tumor site.

• Generation and Source: 19E12 was generated by immunizing 129 strain mice with AKR SL3 leukemia cells and fusing the lymphocytes with a BALB/c-derived myeloma line. It is specific for Thy1.1 but does not cross-react with Thy1.2, making it a key tool for distinguishing between mouse strains or engineered cell populations.

• Context-Dependent Effects: Thy1.1 involvement (and thus the application of 19E12) is context-dependent, modulating not just immune functions but also cancer progression, fibrosis, and neuronal injury, as cited in various literature.

In scientific research, 19E12 is frequently referenced for its role in cell sorting, depletion, lineage tracing, and preclinical therapeutics studies in mouse models where Thy1.1 serves as a distinguishing or selectable marker.

Dosing regimens for clone 19E12 (anti-mouse Thy1.1, CD90.1) are not standardized and vary depending on the mouse model, experimental objective, and combination with other agents. Available references and product information provide limited details on dosing schedules, but key findings can be summarized:

• Mouse strain and tumor models: 19E12 has been used primarily in 129 strain mice, AKR parental mice, and (B6 x AKR)F1 hybrids, often in the context of leukemia or lymphoma models where the Thy1.1 antigen is expressed.
• Administration details: While the specific amount (µg or mg per mouse) and frequency of 19E12 dosing are not explicitly detailed in most sources, efficacy is reported when 19E12 is administered alone or with other monoclonal antibodies (such as rat mAb R17 208) in tumor-bearing mice.
• Combination regimens: Antitumor activity of 19E12 is enhanced when given in combination with other antibodies, suggesting flexibility in regimen design depending on the immunotherapeutic context.
• Applications: Beyond therapy, 19E12 has been employed in creating bispecific antibodies and in pretargeting strategies with biotinylated forms for certain tumor targeting protocols.

In summary:
The specific dosing regimens (dose per mouse, frequency, route) for clone 19E12 are not standardized and are adapted to experimental context, mouse strain, tumor type, and combination strategies. Directly cited product documentation and historical studies confirm its use primarily in tumor immunotherapy models, but do not specify a universal or preferred dose or schedule.

If you require precise dosing (e.g., mg per mouse, frequency), consulting original research articles where 19E12 is applied in vivo, or contacting vendors like Leinco directly for updated protocols, is recommended. The absence of explicit regimens in the provided results indicates that protocols are study-dependent and should be individually validated for each experimental setup.